<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528967</url>
  </required_header>
  <id_info>
    <org_study_id>EG01</org_study_id>
    <nct_id>NCT03528967</nct_id>
  </id_info>
  <brief_title>Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women</brief_title>
  <acronym>PRESANCE</acronym>
  <official_title>Enoxaparine en PREvention Des insuffiSAnces Placentaires Chez Les Femmes eNCEintes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin
      treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant
      women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, prospective, monocentric, open-label comparative study with two parallel groups
      (Enoxaparin, at a preventive dose, combined with Aspirin versus Aspirin alone), with the main
      objective being to evaluate the effectiveness of enoxaparin, at a preventive dose, in
      reducing placental insufficiency during pregnancy in pregnant women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2013</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of maternal death</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the incidence of maternal death between the two arms of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence rate of preeclampsia</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the recurrence rate of preeclampsia between the two arms of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of intrauterine growth restriction (IUGR)</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the incidence of IUGR between the two arms of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of retroplacental hematoma (RPH)</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the incidence of RPH between the two arms of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of perinatal death</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the incidence of perinatal death between the two arms of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of miscarriage</measure>
    <time_frame>13 - 21 weeks of amenorrhea</time_frame>
    <description>To compare the incidence of miscarriage between the two arms of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in utero fetal death (IUFD)</measure>
    <time_frame>22 weeks of amenorrhea at birth</time_frame>
    <description>To compare the incidence of IUFD between the two arms of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neonatal death</measure>
    <time_frame>From birth to 28 days of life</time_frame>
    <description>To compare the incidence of neonatal death between the two arms of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>7 - 42 weeks of amenorrhea</time_frame>
    <description>To compare the safety of both study products</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Placental Insufficiency</condition>
  <condition>Enoxaparin</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:
Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily
Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily
Start treatment from inclusion visit
Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:
Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily
Administer orally
Start treatment from inclusion visit
Maintain treatment until 35 Weeks of Amenorrhea (WA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 mg / 0.4 mL Prefilled Syringe</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100 mg Oral Tablet, Enteric Coated</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and

          -  Age ≤ 45 years and

          -  Single and confirmed pregnancy and

          -  Intrauterine growth restriction (IUGR) history with an estimated fetal weight (ESW) &lt;
             3rd percentile and / or

          -  In utero fetal death (IUFD) history &gt; 12 weeks of amenorrhea (WA) and / or

          -  Central Retroplacental hematoma (RPH) history &lt; 34 WA and / or

          -  History of severe preeclampsia &lt; 34 WA and

          -  Informed consent, written and obtained

        Exclusion Criteria:

          -  Age &lt;18 years or

          -  Age &gt; 45 years or

          -  Multiple pregnancy or

          -  Pregnancy &gt; 7 WA or

          -  Positive immunological assessment or

          -  Known history of Thromboembolic diseases, Hemorrhagic diseases, Systemic Lupus
             Erythematosus (SLE), Heparin-induced thrombocythemia (HIT), Suspicion of thrombophilia
             (burdened history) or an episode of Deep Vein Thrombosis (DVT) or

          -  Anticoagulation required or

          -  Thrombocythaemia &lt; 100,000 plq / µl or

          -  Weight &gt; 100 kg or

          -  Osteoporosis or

          -  Known allergy to the study products or

          -  Inability to ensure injections' administration or

          -  Family history of DVT before 40 years of age or
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalenda Chelly, OB/GYN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wassila Bourguiba Hospital Tunis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maternity Center of Wassila Bourguiba Hospital - Department A</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placental Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

